Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors

Journal of Molecular Endocrinology

Volumn 32, Issue 3, 2004, Pages 869-877

  Nicol, Moira R ^a   Cobb, V J ^a   Williams, B C ^a   Morley, S D ^a   Walker, S W ^a   Mason, J I ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; HORMONE RECEPTOR STIMULATING AGENT; HYDROCORTISONE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LIGAND; RECEPTOR SUBTYPE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ADRENAL CORTEX TUMOR; ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROCORTISONE RELEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PURINE SYNTHESIS; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION; STEROIDOGENESIS; STRUCTURAL HOMOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROCORTISONE; NERVE GROWTH FACTORS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN ISOFORMS; RADIOIMMUNOASSAY; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; VASOACTIVE INTESTINAL PEPTIDE;

EID: 3042818429     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0320869     Document Type: Article

References (37)

1. Adamou JE, Aiyar N, Vanhorn S & Elshourbagy NA 1995 Cloning and functional characterisation of the human vasoactive intestinal polypeptide (VIP)-2 receptor. Biochemical and Biophysical Research Communications 209 385-392.
2. 1 adrenergic receptors. Neuroscience Letters 166 109-112.
3. Bornstein SR, Hadian A & Ehrhart-Bornstein M 1996 Cellular communication in the neuroadrenocortical axis: role of vasoactive intestinal polypeptide (VIP). Endocrine Research 22 819-829.
4. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anaytical Biochemistry 72 248-254.
5. Cobb VJ, Williams BC, Mason JI & Walker SW 1996 Forskolin treatment directs steroid production towards the androgen pathway in the NCI-H295R adrenocortical tumour cell line. Endocrine Research 22 545-550.
6. Corbitt J, Hagerty T, Fernandez E, Morgam WW & Strong R 2002 Transcriptional and post-transcriptional regulation of tyrosine hydroxylase messenger RNA in PC12 cells during persistent stimulation by VIP and PACAP38: differential regulation by protein kinase A and protein kinase C-dependent pathways. Neuropeptides 36 34-45.
7. Couvineau A, Rouyerfessard C, Darmoul D, Maoret JJ, Carrero I, Ogierdenis E & Laburthe M 1994 Human intestinal VIP receptor - cloning and functional expression of 2 cDNA-encoding proteins with different N-terminal domains. Biochemical and Biophysical Research Communications 200 769-776.
8. Cunningham LA & Holwarth MA 1989 Autoradiographic distribution of I-125 VIP binding in the rat adrenal-cortex. Peptides 10 1105-1108.
9. Dickinson T & Fleetwood-Walker SM 1999 VIP and PACAP: very important in pain? Trends in Pharmacological Science 20 324-329.
10. Edwards AV & Jones CT 1993 Autonomic control of adrenal function. Journal of Anatomy 183 291-307.
11. Ehrhart-Bornstein M, Bornstein SR, Scherbaum WA, Pfeiffer EF & Holst JJ 1991 Role of vasoactive intestinal peptide in a neuroendocrine regulation of the adrenal cortex. Neuroendocrinology 54 623-628.
12. Goutler P, Deneef P, Cnudde J, Waelbroeck M & Robberecht P 1997a In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18 1555-1560.
13. Gourlet P, Vandermeers A, Vertongen P, Rathe J, Deneef P, Cnudde J, Waelbroeck M & Robberecht P 1997b Development of high affinity selective VIP1 receptor agonists. Peptides 18 1539-1545.
14. Gourlet P, Vertongen P, Vandermeers A, Vandermeers-Pirit MC, Rathe J, Deneef P, Waelbroeck M & Robberecht P 1997c The long-acting vasoactive intestinal polypeptide agonist RO25-1553 is highly selective of the VIP2 receptor subclass. Peptides 18 403-408.
15. Gozes I, Fridkinb M, Hill JM & Brenneman DE 1999 Pharmaceutical VIP: prospects and problems. Current Medical Chemistry 6 1019-1034.
16. Gressens P, Hill JM, Gozes I, Fridkin M & Brenneman DE 1993 Growth factor functions of vasoactive intestinal peptide in whole cultured Mouse embryos. Nature 362 155-158.
17. Haidan A, Hilbers U, Bornstein SR & Ehrhart-Bornstein M 1998 Human adrenocortical NCI-H295R cells express VIP receptors. Steroidogenic effect of vasoactive intestinal polypeptide (VIP). Peptides 19 1511-1517.
18. Harmar AJ, Marston HM, Shen S, Spratt C, West KM, Sheward WJ, Morrison CF, Dorin JR, Piggins HD, Reubi JC et al. 2002 The VPAC2 receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell 109 497-508.
19. Hinson JP, Kapas S, Orford CD & Vinson GP 1992 Vasoactive intestinal peptide stimulation of aldosterone secretion by the rat adrenal cortex may be mediated by the local release of catecholamines. Journal of Endocrinology 133 253-258.
20. Hinson JP, Purbrick A, Cameron LA & Kapas S 1994 The role of neuropeptides in the regulation of adrenal zona-fasciculata reticularis function - effects of vasoactive intestinal polypeptide, substance-P, neuropeptide-Y, Met-enkephalin and Leu-enkephalin and neurotensin on corticosterone secretion in the intact perfused rat adrenal gland in situ. Neuropeptides 26 391-397.
21. Ishihara T, Shigemoto R, Mori K, Takahashi K & Nagata S 1992 Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8 811-819.
22. Laburthe M, Couvineau A & Marie J-C 2002 VPAC receptors for VIP and PACAP. Receptors and Channels 8 137-153.
23. Mazzocchi G, Malendowicz LK, Rebuffat P, Gottardo G & Nussdorfer G 2002 Expression and function of vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide and their receptors in the human adrenal gland. Journal of Clinical Endocrinology and Metabolism 87 2575-2580.
24. Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N & Arimura A 1990 Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochemical and Biophysical Research Communications 63 643-648.
25. Piggins HD & Cutler DJ 2003 The roles of vasoactive intestinal polypeptide in the mammalian circadian clock. Journal of Endocrinology 177 7-15.
26. Rainey WE, Bird IM, Sawetawan C, Hanley NA, McCarthy JL, McGee EA, Wester R & Mason JI 1993 Regulation of human adrenal carcinoma cell (NCI-H295) production of C19 steroids. Journal of Clinical Endocrinology and Metabolism 77 731-737.
27. Rainey WE, Bird IM & Mason JI 1994 The NCI-H295 cell line: a pluripotent model for human adrenocortical studies. Molecular and Cellular Endocrinology 100 45-50.
28. Rang HP, Dale M & Ritter JM 1999 How drugs act: general principles. In Pharmacology. 4th edn. p 2-18, Ed J Ritter. New York, Churchill Livingstone.
29. Said SI 2000 VIP and PACAP in pain and inflammation. Trends in Pharmacological Science 21 57.
30. Said SI & Mutt V 1970 Polypeptide with broad biologic activity: isolation from small intestine. Nature 225 863-864.
31. Shivers BD, Gorcs TJ, Gottschall PE & Arimura A 1991 High affinity binding sites for pituitary adenylate cyclase-activating polypeptide have different tissue distributions. Endocrinology 128 3055-3065.
32. Sreedharan SP, Patel DR, Huang JX & Goetzl EJ 1993 Cloning and expression of a novel human neuroendocrine VIP receptor. FASEB Journal 7 A1112.
33. Svoboda M, Tastenoy M, van-Rampelbergh J, Goossens JF, Deneef P, Waelbroeck M & Robberecht P 1994 Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochemical and Biophysical Research Communications 205 1617-16224.
34. Usdin TB, Bonner TI & Mezey E 1994 Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135 2662-2680.
35. Wakade TD, Blank MA, Malhotra RK, Pourcho R & Wakada AR 1991 The peptide VIP is a neurotransmitter in rat adrenal-medulla; physiological role in controlling catecholamine secretion. Journal of Physiology - London 444 349-362.
36. Williams BC, Lightly ERT, Ross AR, Bird IM & Walker SW 1989 Characterization of the steroidogenic responsiveness and ultrastructure of purified zona fasciculata/reticularis cells from bovine adrenal cortex before and after primary culture. Journal of Endocrinology 121 317-324.
37. Yamaguchi N 1993 In vivo evidence for adrenal catecholamine release mediated by non-nicotinic mechanism - local medullary effect of VIP. American Journal of Physiology 265 R766-R771.